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Aims. Much of the diabetes burden is caused by its complications. This cross-sectional study aimed to determine the prevalence and
risk factors for diabetic microvascular complications (retinopathy, nephropathy, and neuropathy) in a high-risk population.
Methods. We collected information via a structured questionnaire and directly from the patient’s record on 1034 adult type 2
diabetic patients who were attending outpatient clinics in Qatar. Results. The mean age of the patients was 55± 10 years, and the
mean duration of diabetes was 12.4± 8.9 years. Forty-five percent had one or more microvascular complications. Shared risk
factors for multiplicity and for individual complications included family history, severity and duration of diabetes, and
hypertension, but some risk factors were specific for individual microvascular complications. Early age at onset of diabetes was
strongly associated with multiplicity of complications (P = 0 0003). Conclusions. About half the diabetics in this high-risk
population had one or more microvascular complications. Several well-established risk factors were associated with multiplicity
and individual microvascular complications, but each separate microvascular complication was linked to a somewhat different
constellation of risk factors.
1. Introduction
Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United
Arab Emirates constitute the members of the Gulf Coopera-
tion Council (GCC) and have high prevalence rates of type 2
diabetes [1]. In Qatar, the burden of diabetes is particularly
high, with an estimated 4.35 years of disability adjusted life
years directly attributable to this cause [2].
Elsewhere in the Middle East, diabetes is also prevalent,
mirroring the current global epidemic of diabetes [3]. The
high prevalence of obesity and lack of exercise, along with
the possibility of region-specific genetic mutations associated
with diabetes, may be the explanation, thereby further con-
firming the genetic peculiarity of some populations [4, 5].
Complications of diabetes contribute greatly to the
increased mortality and morbidity associated with this
disease. Diabetic complications are customarily divided
into two main categories: macrovascular complications,
including heart disease and stroke, and microvascular com-
plications, which include retinopathy, nephropathy, and
neuropathy. In the multinational A1chieve study, a large
global study, based on nearly 68,000 type 2 diabetics, micro-
vascular complications accounted for about half the total
number of complications [6].
Microvascular complications, the focus of this report, are
a leading cause of blindness, kidney failure, and lower limb
amputation. It is unclear why some diabetic patients develop
microvascular complications and other patients do not.
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Previous investigators have pointed out that the links
between the various microvascular complications need
further exploration [7, 8] and only limited data are available
about their prevalence in Qatar.
The aims of this study performed in the type 2 diabetic
adult population of Qatar were to (1) examine the frequency
and overlap of microvascular complications, (2) determine
risk factors for individual diabetic complications, and (3)
determine if smoking, a risk factor for diabetes, was also asso-
ciated with microvascular complications.
2. Materials and Methods
2.1. Study Subjects. The information in this report came from
a cross-sectional survey conducted among patients attend-
ing the outpatient clinics of Hamad General Hospital, the
largest tertiary care hospital in Doha, the capital of Qatar.
Data were collected from June 2013 to January 2015 using
a detailed questionnaire (supplementary file available on
request) covering patient background information, health
status, tobacco use, chronic disease history, and family his-
tory. Trained personnel from the Division of Global and
Public Health (now Institute for Population Health), Weill
Cornell Medicine-Qatar, completed the questionnaire
while interviewing patients at the time of their clinic visit.
The patients were recruited from the diabetic, endocrine,
gastroenterology, ophthalmology, nephrology, dietetic,
podiatry, and smoking cessation clinics. The inclusion cri-
teria for recruitment were age≥ 18 and previous diagnosis
of diabetes. Exclusion criteria included subjects less than
18 years of age, subjects diagnosed with type I diabetes,
and those with gestational diabetes. In addition to infor-
mation obtained directly from patients, the interviewer
also collected information from the patient’s chart relating
to current findings on physical examination, medication
use, and laboratory data. Detailed smoking questions were
included in the questionnaire because smoking is a known
risk factor for diabetes, but its relationship to various com-
plications has not been well documented. Because of the
low prevalence of smoking in the female population of this
region (less than one percent of Qatari women smoke, and
the prevalence of smoking in non-Qatari women is only
about 3%) [9], we prematurely stopped the enrollment of
female diabetic patients in the study on May 15, 2014,
concentrating our resources and effort to male diabetics.
To achieve diagnostic homogeneity in the study, we lim-
ited participants to adults (age 18 or more) diagnosed with
type 2 diabetes.
2.2. Ethical Considerations. The study was reviewed and
approved by the Research Office at Weill Cornell Medicine-
Qatar and the Research Committee at Hamad Medical
Corporation. Patient participation in the study was entirely
voluntary, and less than 2% of patients who were approached
opted out of the study. Prior to the interview, a statement
regarding the study embodying the elements of consent was
read out to the subjects and verbal consent was obtained
from each recruited subject.
2.3. Statistical Analysis. The study sample size (800 men) was
calculated to detect a 10% difference in the prevalence of
complications among male diabetic smokers, corresponding
to an odds ratio = 1.5, assuming that 45% of men ever
smoked and that the prevalence of complications is 50% in
nonsmokers, using a two-sided Z test with pooled variance.
Association between sociodemographic, lifestyle, and past
medical history characteristics and the number of complica-
tions was assessed with the Mantel-Haenszel test for trend
(categorical variables) and analysis of variance (ANOVA)
for continuous variables. Odds ratios (OR) and 95% confi-
dence intervals (CI) for the association between patients’
characteristics and microvascular disease were estimated
using logistic regression models adjusted for age, gender,
and duration of diabetes. Multivariable logistic regression
was then used to assess independence of the associations, fit-
ting together all the variables that were associated with out-
come in the previous analysis. Factors considered for
inclusion in the multivariable analysis included the following:
age (per 10-year increase), gender, duration of diabetes (10 or
more years versus less than 10 years), education level, first
degree family history of diabetes (yes versus no), insulin
treatment (yes versus no), body mass index (per 5 kg/m2),
history of hypertension under treatment, blood pressure
(stage 1 or 2 hypertension (≥140/≥90) versus normal or
prehypertension), LDL level (per 1 unit increase), HbA1c
blood level (per 1 unit increase), and high creatinine level
(>106 versus ≤106 μmol/L). All analyses were performed
with SAS version 9.4 (Cary, NC). All P values were two-
sided. P values < 0.05 were considered statistically significant.
3. Results and Discussion
3.1. Results. Table 1 contains information about the 1034
patients with type 2 diabetes mellitus who were included in
the analysis. The mean age (±standard deviation) of patients
was 55 years± 10 years (range 18–84). The average patient
age at onset of diabetes was 43± 11 years, the average dura-
tion of diabetes was 12.4± 9.0 years, and the mean glycated
hemoglobin (HbA1c) level was 8.3± 1.8%. Forty-six percent
of male patients were current or former smokers, while only
2 (0.8%) of female patients ever smoked. Gender-specific
participants’ characteristics are available in Supplementary
Tables 1a and 1b.
When compared to patients with no complications, sev-
eral variables were associated with multiplicity of complica-
tions. These included age, gender, education, family history,
duration, and age at onset of diabetes, HbA1c level, diabetic
therapy, LDL, creatinine levels, and elevated systolic blood
pressure.
Table 2 and Figure 1 provide information about the
frequency of individual and combinations of complica-
tions, overall and by gender. We stratified microvascular
complications into the same major groups used by other
authors: nephropathy, neuropathy, and retinopathy [4].
Microvascular complications were present at the time of the
survey in 48.4% (n = 500) of patients; 30.8% (n = 318) had
one complication; 13.5% (n = 140) had two microvascular
complications, and only 4.1% (n = 42) had all three
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Table 1: Participant characteristics.
All Number of complications∗
Patients None 1 ≥2 P value ∗∗
N (%) N (%) N (%) N (%)
All 1034 (100) 534 (100) 318 (100) 182 (100)
Age (mean, SD), years 55± 10 53± 11 57± 10 59± 9 <0.0001
Sex
Males 798 (77.2) 442 (82.8) 228 (71.7) 128 (70.3)
Females 236 (22.8) 92 (17.2) 90 (28.3) 54 (29.7) <0.0001
Nationality
Qatari 419 (40.5) 202 (37.8) 127 (39.9) 90 (49.5)
Non-Qatari 615 (59.5) 332 (62.2) 191 (60.1) 92 (50.5) 0.01
Education
≤High school 538 (52.0) 250 (46.8) 170 (53.5) 118 (64.8)
>High school 496 (48.0) 284 (53.2) 148 (46.5) 64 (35.2) <0.0001
Household monthly income
<$2750 257 (33.3) 140 (32.7) 74 (32.3) 43 (37.1)
$2750–5500 235 (30.4) 126 (29.4) 72 (31.4) 37 (31.9)
≥$5500 281 (36.3) 162 (37.9) 83 (36.2) 36 (31.0) 0.26
Family history of diabetes
No 348 (35.1) 211 (40.5) 100 (33.8) 37 (21.3)
Yes 643 (64.9) 310 (59.5) 196 (66.2) 137 (78.7) <0.0001
Duration of diabetes
Less than 10 years 453 (43.8) 330 (61.8) 102 (32.1) 21 (11.5)
10 or more years 581 (56.2) 204 (38.2) 216 (67.9) 161 (88.5) <0.0001
Age at onset of diabetes, years 43± 11 44± 10 43± 11 39± 11 <0.0001
HbA1c, percent 8.3± 1.8 8.0± 1.8 8.4± 1.7 9.0± 1.9 <0.0001
Treatment for diabetes
Drug 549 (53.6) 338 (64.1) 162 (51.3) 49 (26.9)
Insulin 436 (42.5) 161 (30.6) 145 (45.9) 130 (71.4)
Other 40 (3.9) 28 (5.3) 9 (2.9) 3 (1.7) <0.0001
BMI, kg/m2 30.8± 6.5 30.1± 6.4 31.1± 6.4 32.1± 6.9 0.001
Normal weight 163 (17.5) 94 (19.8) 45 (15.6) 24 (14.5)
Overweight 320 (34.5) 177 (37.3) 92 (31.9) 51 (30.7)
Obese 446 (48.0) 204 (42.9) 151 (52.4) 91 (54.8) 0.005
Smoking status
Never smoked regularly 665 (64.3) 335 (62.7) 202 (63.5) 128 (70.3)
Ever smoke regularly 369 (35.7) 199 (37.3) 116 (36.5) 54 (29.7) 0.10
LDL, mmol/L 2.5± 0.9 2.6± 0.9 2.4± 0.9 2.4± 1.0 0.02
Cholesterol, mmol/L 4.4± 1.1 4.5± 1.1 4.3± 1.1 4.2± 1.3 0.05
Creatinine, μmol/L 93± 52 83± 34 94± 49 120± 80 <0.0001
≤106 μmol/L 819 (80.5) 475 (91.4) 241 (76.5) 103 (56.6)
>106 μmol/L 198 (19.5) 45 (8.6) 74 (23.5) 79 (43.4) <0.0001
History of hypertension
No 361 (34.9) 236 (44.2) 89 (28.0) 36 (19.8)
Yes 673 (65.1) 298 (55.8) 229 (72.0) 146 (80.2) <0.0001
Systolic BP, mmHg 138± 18 136± 17 140± 19 143± 19 <0.0001
Diastolic BP, mmHg 76± 11 77± 10 77± 12 74± 10 0.01
∗Retinopathy, nephropathy, and neuropathy following the diagnosis of diabetes. ∗∗P value using theMantel-Haenszel test for trend for categorical variables and
ANOVA for continuous variables. SD: standard deviation; HbA1c: hemoglobin A1c; LDL: low-density lipoprotein; BP: blood pressure.
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microvascular complications. Significantly more women
than men reported any microvascular complication (61.0%
versus 44.6%, P < 0 0001).
Three hundred (29.0%) patients reported neuropathy,
266 (25.7%) retinopathy, and 158 (15.3%) nephropathy.
Female patients had higher prevalence of neuropathy
(45.8% versus 24.1%, P < 0 0001) and retinopathy (32.2%
versus 23.8%, P = 0 01) but lower prevalence of nephropathy
(10.6% versus 16.7%, P = 0 02) than male patients.
The mean age at development of all three microvascular
complications was similar and ranged from 53.3± 9.2 years
(neuropathy) to 55.2± 10.6 years (nephropathy). Similarly,
the mean interval between the diagnosis of diabetes and the
development of microvascular complications was also simi-
lar, ranging from 12.9± 8.5 years (neuropathy) to 14.4± 8.1
years (retinopathy).
Table 3 presents the results of a multivariable analysis of
all factors that were associated with diabetes in after sole
adjustment for age, gender, and duration of diabetes (results
available in Supplementary Table 2). Several variables were
significantly associated with one or more microvascular com-
plications, but HbA1c was the only variable significantly
associated with all three complications in the fully adjusted
model. Each of the three major microvascular complications
had a distinct pattern of associated risk factors.
3.2. Discussion. This study focused on the prevalence of
major complications in previously diagnosed adult male
diabetics attending outpatient clinics at Hamad General
Hospital that is a major provider of health care for the
diabetic population of Doha, the capital of Qatar. In these
adult type 2 diabetic patients, about half developed one or
more microvascular complications 12–14 years after the
onset of diabetes. In patients who did develop complica-
tions, about two-thirds developed a single complication
and one-third developed two or more complications.
The role of smoking as an important risk factor for diabe-
tes needs further emphasis: about half the subjects in this
group of male diabetics were current or ex-smokers. The
increased prevalence of smoking in these patients is under-
standable since smoking is known to be an important risk
factor for diabetes [10]. However, even though smoking is
known to be related with diabetes, smoking status (ever
versus never) was unrelated to the presence or absence of
microvascular complications nor to the development of any
single microvascular complication, perhaps because smoking
has equal effects on the microcirculation in the various sites
were microvascular complications are diagnosed.
Table 2: Prevalence of major microvascular complications in 1034 patients with type 2 diabetes in Qatar, by gender.
All Males Females
P value
N (%) N (%) N (%)
Total number of patients 1034 (100) 798 (100) 236 (100)
Number of complications <0.0001
None 534 (51.6) 442 (55.4) 92 (39.0)
One complication 318 (30.8) 228 (28.6) 90 (38.1)
Retinopathy 108 (10.4) 81 (10.2) 27 (11.4) 0.55
Nephropathy 55 (5.3) 50 (6.3) 5 (2.1) 0.01
Neuropathy 155 (15.0) 97 (12.2) 58 (24.6) <0.0001
Two complications 140 (13.5) 97 (12.2) 43 (18.2)
Retinopathy + nephropathy 37 (3.6) 33 (4.1) 4 (1.7) 0.11
Retinopathy + neuropathy 79 (7.6) 45 (5.6) 34 (14.4) <0.0001
Nephropathy + neuropathy 24 (2.3) 19 (2.4) 5 (2.1) 1.00
Three complications 42 (4.1) 31 (3.9) 11 (4.7) 0.58
Patterns of combined complications
Retinopathy (±other complications) 266 (25.7) 190 (23.8) 76 (32.2) 0.01
Nephropathy (±other complications) 158 (15.3) 133 (16.7) 25 (10.6) 0.02


















NONE: 534 (51.6%) 
Figure 1: Prevalence of major microvascular complications in 1034
patients with type 2 diabetes in Qatar.
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In general, factors that were associated with multiplicity
of microvascular complications listed in Table 1 were similar
to those related to each individual complication. Age at onset
of diabetes was strongly associated with increasing number of
complications. Multiple complications were inversely associ-
ated with age: patients with two or more complications were
significantly younger than patients without any microvascu-
lar complications. In other regions, studies that have looked
at age of onset of diabetes have found that early onset diabe-
tes, usually defined as <45 years, increases disease severity.
This observation suggests that patients with early onset of
diabetes have a more aggressive disease and are prone to
develop more complications at an earlier age [11–13].
Genetic determinants of diabetes are likely to be more com-
mon in patients with early onset of diabetes [14]. Our report
agrees with other studies that the early onset of diabetes
could be a helpful prognostic variable to predict the develop-
ment of microvascular complications.
HbA1c was the only factor significantly associated with
all three microvascular complications, although hypertension
(current or under treatment) achieved borderline signifi-
cance (P = 0 06). This finding implies that careful diabetic
control is a worthwhile and achievable goal for minimizing
the excess disability and costs associated with diabetes [15].
Of interest, each individual microcirculatory complication
was associated with its own somewhat different pattern of
risk factors. In addition to HbA1c levels and hypertension,
these included patient age, family history, duration of diabe-
tes, insulin use, and body mass index. In particular, concern-
ing bodymass index, it is well known that obesity predisposes
to type 2 diabetes, a condition for which even a moderate
weight loss can improve insulin resistance and chronic
hyperglycemia, both of which are related to microvascular
complications [16, 17].
This study has several weaknesses: it is cross-sectional
and therefore not the best design for studying temporal
changes. Although the possibility of interviewer bias exists,
we believe that it should not affect our main findings since
information about diabetic complications and treatment are
not subjective and were corroborated with data retrieved
from clinical charts. Also, participants were entirely volun-
tary and interviews were conducted by trained personnel.
Since it is based on a clinic population, we have no informa-
tion about the number of deaths or the causes of antecedent
mortality, which could skew our results. As an example,
smoking could be a major causative factor for deaths in this
clinic population. Since this is a single institution study, the
results and in particular the prevalence of complications
may not be generalized; however, it was conducted in the
largest tertiary care hospital in Doha, which is the most rep-
resentative institution in the country. Furthermore, we report
only microvascular and not macrovascular complications.
The study strengths are that the information comes
from a carefully followed group of adult diabetics from a
region with a high prevalence of diabetes. The Qatari
and non-Qatari were similar, indicating that the findings
are likely to be generalizable to the large population of
male diabetics in the Middle East and perhaps to other
regions. Another strength of the study is that it provides
a road map to help guide diabetologists to compare and
assess the likelihood of development of microvascular
complications in their patients, as well as to determine
the relative importance of individual risk factors for the
individual type of complications.
In conclusion, this report provides information about the
prevalence of individual and multiple microvascular compli-
cations among diabetics in Qatar, which has among the high-
est incidence rates of diabetes globally. The frequency of
individual microvascular complications is generally similar
to reports based on similarly aged patients from the same
region [18–21] and from other regions [22–24]. However,
unlike many previous reports which focus on a single compli-
cation, this report provides information for clinicians about
the timing, the overlap, the pattern of development, and the
risk factors associated with multiple microvascular complica-
tions. This information can be useful to diabetologists and
clinicians responsible for the management of the large group
of diabetics who develop microvascular complications.
Table 3: Multivariable analysis of factors associated with microvascular complications.
Variable
Retinopathy Nephropathy Neuropathy∗
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Age (per 10 years) 1.19 (1.00–1.43) 0.05 0.87 (0.69–1.11) 0.27 1.18 (1.00–1.39) 0.06
Gender (female versus male) 1.34 (0.92–1.95) 0.13 0.95 (0.53–1.70) 0.85 2.07 (1.44–2.97) <0.0001
Duration of DM≥ 10 years 3.83 (2.56–5.72) <0.0001 1.48 (0.87–2.49) 0.15 2.77 (1.92–3.99) <0.0001
Education (>high school) 0.79 (0.57–1.10) 0.16 0.61 (0.38–0.96) 0.03 —
Family history of DM (yes versus no) — — 1.63 (1.15–2.30) 0.006
HbA1c level (per % increase) 1.14 (1.04–1.25) 0.006 1.15 (1.00–1.33) 0.05 1.12 (1.02–1.23) 0.01
DM treatment (insulin versus drug) 1.61 (1.14–2.26) 0.006 2.05 (1.25–3.39) 0.005 1.26 (0.90–1.75) 0.18
Body mass index (per 5 kg/m2) — — 1.29 (1.14–1.47) <0.0001
LDL (per mmol/L increase) — 0.82 (0.64–1.05) 0.11 —
Creatinine (>106 versus ≤106 μmol/L) 1.63 (1.11–2.41) 0.01 23.9 (14.7–38.8) <0.0001 1.36 (0.93–1.99) 0.12
Hypertension or high BP 1.87 (1.29–2.71)1 0.001 2.03 (1.15–3.59)1 0.01 1.31 (0.97–1.78)2 0.08
Odds ratios (OR) and 95% confidence intervals (CI) obtained from multivariable logistic regression model with all displayed variables fitted simultaneously.
∗Foot ulcer and amputation. 1History of hypertension, undergoing treatment. 2Systolic blood pressure ≥ 140 or diastolic blood pressure ≥ 90 at time of survey
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